Download PDF
Horm Metab Res 2008; 40(11): 801-805
DOI: 10.1055/s-0028-1082040
Humans, Clinical

© Georg Thieme Verlag KG Stuttgart · New York

Intensive Glycemic Control Lowers Plasma Visfatin Levels in Patients with Type 2 Diabetes

J. Zhu 1 , 3 , M. Schott 2 , R. Liu 1 , C. Liu 1 , B. Shen 1 , Q. Wang 1 , X. Mao 1 , K. Xu 1 , X. Wu 1 , S. Schinner 2 , C. Papewalis 2 , W. A. Scherbaum 2 , C. Liu 1 , 2
  • 1Department of Endocrinology, First Affiliated Hospital, Nanjing Medical University, Nanjing, China
  • 2Department of Endocrinology, Diabetes and Rheumatology, University Hospital Düsseldorf, Düsseldorf, Germany
  • 3Department of Endocrinology, Nanjing First Hospital, Nanjing Medical University, Nanjing, China
Further Information

Publication History

received 10.01.2008

accepted 17.04.2008

Publication Date:
06 August 2008 (online)

Also available at
    Permissions and Reprints

Abstract

Visfatin is an independent association factor for type 2 diabetes mellitus (T2DM). In order to evaluate the plasma visfatin levels and investigate whether plasma visfatin concentrations are altered by intensive glycemic control in patients with diabetes, we determined plasma visfatin concentrations and metabolic parameters in 53 newly diagnosed type 2 diabetic patients and 35 healthy controls. Visfatin levels were also investigated before and after intensive glycemic control for three months in subgroup of patients with T2DM. Plasma visfatin levels were significantly elevated in diabetic patients compared with healthy controls (p<0.001). Circulating visfatin concentration was associated with fasting plasma glucose (FPG), 2-hour OGTT plasma glucose (2hPG), HOMA-β indexes (r=0.338, p=0.001; r=0.340, p=0.002; r=−0.296, p=0.006, respectively), but not with insulin sensitivity (HOMA-IR) or other metabolic or anthropometric parameters in all subjects. In addition, visfatin levels were also correlated with HbA1c levels in diabetic patients. Furthermore, visfatin concentrations reduced from 25.0±6.5 ng/ml at baseline to 20.3±4.7 ng/ml (p<0.01) after 3 months of intensive glycemic control, while HbA1c levels decreased from 9.0±1.8% to 6.2±0.7% (p<0.01). We conclude that the change of visfatin concentration may be a compensatory mechanism to ameliorate insulin deficiency due to pancreatic β-cell dysfunction.

Key words

visfatin - type 2 diabetes mellitus - intensive glycemic control

References

  • 1 Fukuhara A, Matsuda M, Nishizawa M, Segawa K, Tanaka M, Kishimoto K, Matsuki Y, Murakami M, Ichisaka T, Murakami H, Watanabe E, Takagi T, Akiyoshi M, Ohtsubo T, Kihara S, Yamashita S, Makishima M, Funahashi T, Yamanaka S, Hiramatsu R, Matsuzawa Y, Shimomura I. Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.  Science. 2005;  307 426-430
    CrossrefPubMedGoogle Scholar
  • 2 Fischer-Posovszky P, Wabitsch M, Hochberg Z. Endocrinology of adipose tissue-an update.  Horm Metab Res. 2007;  39 314-321
    Article in Thieme ConnectPubMedGoogle Scholar
  • 3 Berndt J, Klöting N, Kralisch S, Kovacs P, Fasshauer M, Schön MR, Stumvoll M, Blüher M. Plasma visfatin concentrations and fat epotspecific mRNA expression in humans.  Diabetes. 2005;  54 2911-2916
    CrossrefPubMedGoogle Scholar
  • 4 Chen MP, Chung FM, Chang DM, Tsai JC, Huang HF, Shin SJ, Lee YJ. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.  J Clin Endocrinol Metab. 2006;  91 295-299
    CrossrefPubMedGoogle Scholar
  • 5 Hammarstedt A, Pihlajamäki J, Rotter Sopasakis V, Gogg S, Jansson PA, Laakso M, Smith U. Visfatin is an adipokine, but it is not regulated by thiazolidinediones.  J Clin Endocrinol Metab. 2006;  91 1181-1184
    CrossrefPubMedGoogle Scholar
  • 6 Arner P. Visfatin: a true or false trail to type 2 diabetes mellitus.  J Clin Endocrinol Metab. 2006;  91 28-30
    CrossrefPubMedGoogle Scholar
  • 7 Pfützner A, Hanefeld M, Lübben G, Weber MM, Karagiannis E, Köhler C, Hohberg C, Forst T. Visfatin: a putative biomarker for metabolic syndrome is not influenced by pioglitazone or simvastatin treatment in nondiabetic patients at cardiovascular risk-results from the PIOSTAT study.  Horm Metab Res. 2007;  39 764-768
    Article in Thieme ConnectPubMedGoogle Scholar
  • 8 Haider DG, Schaller G, Kapiotis S, Maier C, Luger A, Wolzt M. The release of the adipocytokine visfatin is regulated by glucose and insulin.  Diabetologia. 2006;  49 1909-1914
    CrossrefPubMedGoogle Scholar
  • 9 López-Bermejo A, Chico-Julià B, Fernàndez-Balsells M, Recasens M, Esteve E, Casamitjana R, Ricart W, Fernández-Real JM. Serum visfatin increases with progressive beta-cell deterioration.  Diabetes. 2006;  55 2871-2875
    CrossrefPubMedGoogle Scholar
  • 10 Li L, Yang G, Li Q, Tang Y, Yang M, Yang H, Li K. Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects.  Exp Clin Endocrinol Diabetes. 2006;  114 544-548
    Article in Thieme ConnectPubMedGoogle Scholar
  • 11 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation.  Diabet Med. 1998;  15 539-553
    CrossrefPubMedGoogle Scholar
  • 12 Jian WX, Luo TH, Gu YY, Zhang HL, Zheng S, Dai M, Han JF, Zhao Y, Li G, Luo M. The visfatin gene is associated with glucose and lipid metabolism in a Chinese population.  Diabet Med. 2006;  23 967-973
    CrossrefPubMedGoogle Scholar
  • 13 Bonora E, Kiechl S, Willeit J, Oberhollenzer F, Egger G, Meigs JB, Bonadonna RC, Muggeo M. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in caucasian subjects from the general population: the Bruneck study.  Diabetes Care. 2007;  30 318-324
    CrossrefPubMedGoogle Scholar
  • 14 Mills GW, Avery PJ, MacCarthy MI, Hattersley AT, Levy JC, Hitman GA, Sampson M, Walker M. Heritability estimates for β cell function and features of the insulin resistance syndrome in UK families with an increased susceptibility to type 2 diabetes.  Diabetologia. 2004;  47 732-738
    CrossrefPubMedGoogle Scholar
  • 15 Haider DG, Schindler K, Schaller G, Prager G, Wolzt M, Ludvik B. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding.  J Clin Endocrinol Metab. 2006;  91 1578-1581
    CrossrefPubMedGoogle Scholar
  • 16 Böttcher Y, Teupser D, Enigk B, Berndt J, Klöting N, Schön MR, Thiery J, Blüher M, Stumvoll M, Kovacs P. Genetic variation in the visfatin gene (PBEF1) and its relation to glucose metabolism and fat depot specific mRNA expression in humans.  J Clin Endocrinol Metab. 2006;  91 2725-2731
    CrossrefPubMedGoogle Scholar
  • 17 Tsiotra PC, Tsigos C, Yfanti E, Anastasiou E, Vikentiou M, Psarra K, Papasteriades C, Raptis SA. Visfatin, TNF-alpha and IL-6 mRNA expression is increased in mononuclear cells from type 2 diabetic women.  Horm Metab Res. 2007;  39 758-763
    Article in Thieme ConnectPubMedGoogle Scholar
  • 18 Kitani T, Okuno S, Fujisawa H. Growth phase-dependent changes in the subcellular localization of pre-B-cell colony-enhancing factor.  FEBS Lett. 2003;  544 74-78
    CrossrefPubMedGoogle Scholar
  • 19 Samal B, Sun Y, Stearns G, Xie C, Suggs S, MacNiece I. Cloning and characterization of the cDNA encoding a novel human pre-B-cell colonyenhancing factor.  Mol Cell Biol. 1994;  14 1431-1437
    CrossrefPubMedGoogle Scholar
  • 20 Jia SH, Li Y, Parodo J, Kapus A, Fan L, Rotstein OD, Marshall JC. Pre-B cell colony-enhancing factor inhibits neutrophil apoptosis in experimental inflammation and clinical sepsis.  J Clin Invest. 2004;  113 1318-1327
    CrossrefPubMedGoogle Scholar
  • 21 Ye SQ, Zhang LQ, Adyshev D, Usatyuk PV, Garcia AN, Lavoie TL, Verin AD, Natarajan V, Garcia JG. Pre-B-cell-colony-enhancing factor is critically involved in thrombin-induced lung endothelial cell barrier dysregulation.  Microvasc Res. 2005;  70 142-151
    CrossrefPubMedGoogle Scholar
  • 22 Veer E van der, Nong Z, O’Neil C, Urquhart B, Freeman D, Pickering JG. Pre-B-cell colony-enhancing factor regulates NAD+-dependent protein deacetylase activity and promotes vascular smooth muscle cell maturation.  Circ Res. 2005;  97 25-34
    CrossrefPubMedGoogle Scholar
  • 23 Rongvaux A, Shea RJ, Mulks MH, Gigot D, Urbain J, Leo O, Andris F. Pre-B-cell colony-enhancing factor, whose expression is up-regulated in activated lymphocytes, is a nicotinamide phosphoribosyltransferase, a cytosolic enzyme involved in NAD biosynthesis.  Eur J Immunol. 2002;  32 3225-3234
    CrossrefPubMedGoogle Scholar
  • 24 Chen H, Ren A, Hu S, Mo W, Xin X, Jia W. The significance of tumor necrosis factor-alpha in newly diagnosed type 2 diabetic patients by transient intensive insulin treatment.  Diabetes Res Clin Pract. 2007;  75 327-332
    CrossrefPubMedGoogle Scholar
  • 25 Li Y, Xu W, Liao Z, Yao B, Chen X, Huang Z, Hu G, Weng J. Induction of long-term glycemic control in newly diagnosed type 2 diabetic patients is associated with improvement of beta-cell function.  Diabetes Care. 2004;  27 2597-2602
    CrossrefPubMedGoogle Scholar
  • 26 Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Hormonal regulation of the novel adipocytokine visfatin in 3T3-L1 adipocytes.  J Endocrinol. 2005;  185 R1-R8
    CrossrefPubMedGoogle Scholar
  • 27 Kralisch S, Klein J, Lossner U, Bluher M, Paschke R, Stumvoll M, Fasshauer M. Interleukin-6 is a negative regulator of visfatin gene expression in 3T3-L1 adipocytes.  Am J Physiol Endocrinol Metab. 2005;  289 E586-E590
    CrossrefPubMedGoogle Scholar
  • 28 Hector J, Schwarzloh B, Goehring J, Strate TG, Hess UF, Deuretzbacher G, Hansen-Algenstaedt N, Beil FU, Algenstaedt P. TNF-alpha alters visfatin and adiponectin levels in human fat.  Horm Metab Res. 2007;  39 250-255
    Article in Thieme ConnectPubMedGoogle Scholar

Authors state that they have no confl ict of interest.

Correspondence

C. Liu

Department of Endocrinology

First Affiliated Hospital

Nanjing Medical University

300 Guangzhou Rd

210029 Nanjing

P. R. China

Phone: +86/25/83 71 88 36

Fax: +86/25/83 67 40 06

Email: liuchao@nfmcn.com

      >